Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Oct 1999; 81(3): 559–563.
PMCID: PMC2362907
Hormone replacement therapy and risk of epithelial ovarian cancer
D M Purdie,1 C J Bain,1 V Siskind,1 P Russell,2 N F Hacker,3 B G Ward,4 M A Quinn,5 and A C Green6
1Department of Social and Preventive Medicine, The University of Queensland, Medical School, Herston, Queensland, 4006, Australia
2Department of Anatomical Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, 2050, Australia
3Gynaecological Cancer Centre, Royal Hospital for Women, Paddington, 188 Oxford Street, Paddington, New South Wales, 2021, Australia;
4Department of Obstetrics and Gynaecology, The University of Queensland, Royal Brisbane Hospital, Herston, Queensland, 4029, Australia
5Gynaecologic Oncology/Dysplasia Unit, The Royal Women's Hospital, 132 Grattan Street, Carlton, Victoria, 3053, Australia
6Queensland Institute of Medical Research, Royal Brisbane Hospital, Herston, Queensland, 4029, Australia
*Author for correspondence:
Received October 5, 1998; Revised March 19, 1999; Accepted March 24, 1999.
It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case–control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32–4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% Cl 1.54–5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours. © 1999 Cancer Research Campaign
Full Text
The Full Text of this article is available as a PDF (67K).
Articles from British Journal of Cancer are provided here courtesy of
Cancer Research UK